Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells.
分子图谱
暂无数据
点击上传数据
参考文献
• Drahl C.: Chem. and Eng. News, 87, 41 (2009)
• Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005)